Related Experiment Video
Updated: Jul 26, 2025
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
Thilo Gambichler1, Britta Majchrzak-Stiller2, Ilka Peters2
1Skin Cancer Center Ruhr-University, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany. t.gambichler@klinikum-bochum.de.
Background:
Even in the novel immunotherapy era, Merkel cell carcinoma (MCC) remains challenging in its treatment. Apart from Merkel cell polyomavirus (MCPyV) associated MCC, this cancer is linked in about 20% of cases to ultraviolet-induced mutational burden frequently causing aberrations in Notch and PI3K/AKT/mTOR signalling pathways. The recently developed agent GP-2250 is capable to inhibit growth of cells of different cancers, including pancreatic neuroendocrine tumors. The objective of the present study was to investigate the effects of GP-2250 on MCPyV-negative MCC cells.
Methods:
Methods We employed three cell lines (MCC13, MCC14.2, MCC26) which were exposed to different GP-2250doses. GP-2250's effects on cell viability, proliferation, and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively. Flow cytometry was performed for the evaluation of apoptosis and necrosis. Western blotting was implemented for the determination of AKT, mTOR, STAT3, and Notch1 protein expression.
Results:
Cell viability, proliferation, and migration decreased with increasing GP-2250 doses. Flow cytometry revealed a dose response to GP-2250 in all three MCC cell lines. While the viable fraction decreased, the share of necrotic and in a smaller amount the apoptotic cells increased. Regarding Notch1, AKT, mTOR, and STAT3 expression a comparatively time- and dose-dependent decrease of protein expression in the MCC13 and MCC26 cell lines was observed. By contrast, Notch1, AKT, mTOR, and STAT3 expression in MCC14.2 was scarcely altered or even increased by the three dosages of GP-2250 applied.
Conclusions:
The present study indicates GP-2250 having anti-neoplastic effects in MCPyV-negative tumor cells in regard to viability, proliferation, and migration. Moreover, the substance is capable of downregulating protein expression of aberrant tumorigenic pathways in MCPyV-negative MCC cells.
Insights
The novel agent GP-2250 shows anti-neoplastic effects on Merkel cell carcinoma (MCC) cells by reducing viability, proliferation, and migration. This compound also downregulates key protein expressions in ultraviolet-induced, Merkel cell polyomavirus-negative MCC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Merkel cell carcinoma (MCC) presents treatment challenges, even with immunotherapy.
- Approximately 20% of MCC cases are linked to UV radiation, causing mutations in Notch and PI3K/AKT/mTOR pathways.
- GP-2250 is a novel agent investigated for its anti-cancer properties.
Purpose of the Study:
- To investigate the effects of GP-2250 on Merkel cell polyomavirus-negative (MCPyV-negative) MCC cells.
- To evaluate GP-2250's impact on cell viability, proliferation, and migration.
- To determine GP-2250's effect on key signaling pathways in MCC.
Main Methods:
- Utilized three MCC cell lines (MCC13, MCC14.2, MCC26) treated with varying GP-2250 doses.
- Assessed cell viability, proliferation, and migration using MTT, BrdU, and scratch assays.
- Analyzed apoptosis, necrosis via flow cytometry and protein expression (AKT, mTOR, STAT3, Notch1) via Western blotting.
Main Results:
- GP-2250 dose-dependently decreased MCC cell viability, proliferation, and migration.
- Increased necrotic and apoptotic cell fractions were observed with GP-2250 treatment.
- GP-2250 reduced protein expression of Notch1, AKT, mTOR, and STAT3 in MCC13 and MCC26 cells, with varied effects in MCC14.2 cells.
Conclusions:
- GP-2250 exhibits anti-neoplastic effects on MCPyV-negative MCC cells.
- GP-2250 effectively reduces cell viability, proliferation, and migration.
- The agent downregulates aberrant signaling pathways implicated in MCPyV-negative MCC tumorigenesis.
